A4GNT | Alpha-1,4-N-acetylglucosaminyltransferase | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/8017/152731_B_8_1_rna_selected_60x60.jpg) | Tissue enriched |
ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/4860/14118_B_8_6_rna_selected_60x60.jpg) | Group enriched |
ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 | Cancer-related genes CD markers Predicted membrane proteins
| | | | ![](/images/54719/135303_A_3_8_rna_selected_60x60.jpg) | Tissue enhanced |
ACE | Angiotensin I converting enzyme | Candidate cardiovascular disease genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images/2426/ihc_cell_selected_60x60.jpg) | ![](/images/2426/6196_B_7_3_rna_selected_60x60.jpg) | Group enriched |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/26174/58083_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
ACY1 | Aminoacylase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | ![](/images/36175/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/36174/98822_B_8_3_rna_selected_60x60.jpg) | Group enriched |
ACY3 | Aspartoacylase (aminocyclase) 3 | Enzymes
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/39219/83702_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
ADA | Adenosine deaminase | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | ![](/images/4307/ihc_cell_selected_60x60.jpg) | ![](/images/23884/54930_B_9_3_rna_selected_60x60.jpg) | Tissue enriched |
AGR2 | Anterior gradient 2 | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/7912/24376_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
AGR3 | Anterior gradient 3 | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/53942/122039_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
AKR1B10 | Aldo-keto reductase family 1, member B10 (aldose reductase) | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/20280/153432_B_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
AKR1B15 | Aldo-keto reductase family 1, member B15 | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/20280/153432_B_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | Enzymes
| | | ![](/images_static/rna_center.gif) | ![](/images/45957/111687_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
ALDOB | Aldolase B, fructose-bisphosphate | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets
| | ![](/images/2198/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/2198/8304_B_7_2_rna_selected_60x60.jpg) | Group enriched |
ANPEP | Alanyl (membrane) aminopeptidase | CD markers Enzymes Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/2417/6119_B_9_2_rna_selected_60x60.jpg) | Group enriched |
ANXA10 | Annexin A10 | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/5469/142253_B_7_2_rna_selected_60x60.jpg) | Tissue enriched |
ANXA13 | Annexin A13 | Plasma proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/19650/151980_B_9_2_rna_selected_60x60.jpg) | Tissue enhanced |
AOC1 | Amine oxidase, copper containing 1 | Enzymes Predicted secreted proteins
| | ![](/images/31032/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/31033/72999_A_3_5_rna_selected_60x60.jpg) | Group enriched |
APOA1 | Apolipoprotein A-I | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | ![](/images/46715/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/16778/39552_B_8_5_rna_selected_60x60.jpg) | Group enriched |
APOA4 | Apolipoprotein A-IV | Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | ![](/images/2549/ihc_cell_selected_60x60.jpg) | ![](/images/1352/3295_B_9_3_rna_selected_60x60.jpg) | Group enriched |
APOB | Apolipoprotein B | Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/49793/141695_B_9_3_rna_selected_60x60.jpg) | Group enriched |
ARHGDIG | Rho GDP dissociation inhibitor (GDI) gamma | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/53974/122970_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |
ATP4B | ATPase, H+/K+ exchanging, beta polypeptide | Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/45400/ihc_cell_selected_60x60.jpg) | ![](/images/45400/135442_B_8_7_rna_selected_60x60.jpg) | Tissue enriched |
B3GALT5 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/54684/126135_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
B3GNT3 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 | Enzymes Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/24298/55399_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
B3GNT7 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/35625/71235_B_1_4_rna_selected_60x60.jpg) | Tissue enhanced |
B4GALNT2 | Beta-1,4-N-acetyl-galactosaminyl transferase 2 | Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/15721/35487_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
B4GALNT3 | Beta-1,4-N-acetyl-galactosaminyl transferase 3 | Enzymes Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/11404/27749_B_3_3_rna_selected_60x60.jpg) | Tissue enhanced |
BCAS1 | Breast carcinoma amplified sequence 1 | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/51816/143712_A_6_2_rna_selected_60x60.jpg) | Tissue enhanced |
BEST4 | Bestrophin 4 | Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/58564/130831_B_9_1_rna_selected_60x60.jpg) | Group enriched |
BPIFB1 | BPI fold containing family B, member 1 | Plasma proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/24256/55104_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
BTNL8 | Butyrophilin-like 8 | Predicted membrane proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/39738/85503_B_9_8_rna_selected_60x60.jpg) | Group enriched |
C10orf99 | Chromosome 10 open reading frame 99 | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/50920/117820_B_8_4_rna_selected_60x60.jpg) | Group enriched |
C15orf48 | Chromosome 15 open reading frame 48 | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/12943/31347_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |
C17orf78 | Chromosome 17 open reading frame 78 | Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/13699/29955_B_9_1_rna_selected_60x60.jpg) | Group enriched |
C1orf106 | Chromosome 1 open reading frame 106 | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/27499/60321_B_3_5_rna_selected_60x60.jpg) | Tissue enhanced |
CA1 | Carbonic anhydrase I | Enzymes FDA approved drug targets Plasma proteins
| | ![](/images_static/na_center.gif) | | ![](/images/6558/22094_B_9_1_rna_selected_60x60.jpg) | Group enriched |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | ![](/images_static/na_center.gif) | ![](/images/1550/ihc_cell_selected_60x60.jpg) | ![](/images/10102/25628_B_3_8_rna_selected_60x60.jpg) | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | ![](/images/17258/ihc_cell_selected_60x60.jpg) | ![](/images/11089/39733_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/17107/39741_A_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/64258/144292_A_4_3_rna_selected_60x60.jpg) | Tissue enhanced |
CAPN9 | Calpain 9 | Enzymes
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/20398/109529_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
CDH17 | Cadherin 17, LI cadherin (liver-intestine) | Cancer-related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images/23614/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/23616/52784_B_1_6_rna_selected_60x60.jpg) | Group enriched |
CDHR2 | Cadherin-related family member 2 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images/17053/ihc_cell_selected_60x60.jpg) | ![](/images/17053/38962_B_8_5_rna_selected_60x60.jpg) | Group enriched |
CDHR5 | Cadherin-related family member 5 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/9081/24280_B_9_2_rna_selected_60x60.jpg) | Tissue enhanced |
CDX1 | Caudal type homeobox 1 | Transcription factors
| | ![](/images_static/na_center.gif) | ![](/images/55196/ihc_cell_selected_60x60.jpg) | ![](/images/55196/127987_B_9_1_rna_selected_60x60.jpg) | Group enriched |
CDX2 | Caudal type homeobox 2 | Cancer-related genes Transcription factors
| | | | ![](/images/2221/5839_B_9_3_rna_selected_60x60.jpg) | Group enriched |
CEACAM1 | Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) | CD markers Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2146/5909_B_2_1_rna_selected_60x60.jpg) | Tissue enhanced |
CEACAM5 | Carcinoembryonic antigen-related cell adhesion molecule 5 | Cancer-related genes CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | | ![](/images/21/18_B_7_1_rna_selected_60x60.jpg) | Group enriched |
CEACAM6 | Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) | Cancer-related genes CD markers Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/11041/27138_B_8_3_rna_selected_60x60.jpg) | Group enriched |